Delic’s Vision Comes Into Focus With a Flurry of Acquisitions
Ryan Allway
March 11th, 2021
App, Exclusive, Psychedelics, Top Story
Investors have many different options when it comes to building exposure into the psychedelics sector within their portfolios. While some companies are undergoing large-scale and years-long clinical trials to prove efficacy, others are opening wellness clinics or cultivating mushrooms in legal jurisdictions.
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is a relatively new player to the psychedelics public markets space, but its management team has previous deep experience in another highly-regulated industry—cannabis—as former high-level executives at High Times. With its recent flurry of acquisitions, the team’s vision for the future of psychedelics is becoming increasingly clear and compelling to investors and the capital markets.
Let’s take a look at some of the recent acquisitions and why investors may want to take note.
Starting a Home Cultivation Movement
DELIC recently acquired a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits. Before developing and selling tens of thousands of mushroom kits around the world, Homestead Book Company was one of the earliest distributors for High Times and other counterculture publications.
The acquisition enables DELIC to increase the products available on Reality Sandwich, which attracts over 200,000 unique visitors each month. In March, the company expects to launch a new mushroom kit that will have a modern interpretation of the company’s storied history and will include everything a consumer needs to become an at-home mycologist.
The company’s overarching goal is to become a leader in the home cultivation movement by leveraging a combination of educational content, innovative products and complementary products. With psychedelics limited to clinics at the moment, home cultivation could be a cornerstone of the mindfulness and meditative side of the movement.
Click here to receive an investor presentation and corporate updates
Building a Network of Ketamine Clinics
DELIC has also been targeting the “right-now” clinical side of the psychedelics industry with the acquisition of Ketamine Infusion Centers LLC last month. With two ketamine infusion treatment clinics in Arizona and California, the company offers ketamine as a mental health treatment for chronic mental health disorders including depression, anxiety, substance abuse, alcoholism, PTSD, and a range of other mental health disorders. Supported by clinical trials and peer reviewed studies, evidence of the efficacy of ketamine infusions is quickly growing.
By leveraging its existing media assets and connections, Delic hopes to supercharge the ketamine clinic business and scale up over time. DELIC’s access to the public markets could also support a more rapid expansion of the business, which has been growing quarter by quarter.
More recently, the company appointed Kyle Snook, former COO of Actify Neurotherapies, to its Board of Advisors. Actify Neurotherapies was a venture-backed startup that was formerly the largest provider of IV Ketamine Therapies nationwide. Combined with an MBA from Harvard Business School, Snook’s experience in the business will be instrumental to DELIC’s growth.
Amassing a Psilocybin IP Portfolio to Drive Value
DELIC is equally focused on building shareholder value through the acquisition of intellectual property in the psychedelics space with the acquisition of Complex Biotech Discovery Ventures (CBDV). In addition to being a profitable business with over 50 cannabis and psychedelics clients, CBDV’s licensed psilocybin and cannabis research lab is well-equipped for the development of IP.
The company aims to build out an IP portfolio of psilocybin analogs, novel compounds and deliver mechanisms that could pave the way for future medical treatments for depression, anxiety, PTSD and opioid substance abuse. With plans to apply for a dealer’s license, the company could also commercialize its research and IP portfolio over time.
The CBDV acquisition also adds strong scientific talent to DELIC’s overall management team. Dr. Markus Roggen brings a wealth of knowledge and industry experience that’s hard to find given the industry’s nascent stage. This leadership and expertise could help transform other businesses that DELIC acquires and better inform its long-term strategy in the space.
Click here to receive an investor presentation and corporate updates
Looking Ahead
Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) flurry of meaningful acquisitions over the past two months crystalizes its forward vision in the psychedelics space. With a broad focus on education, home cultivation, ketamine wellness clinics and IP psychedelic development, the company provides shareholders with diverse exposure to the industry and what could become a near-term path to profitability for investors.
For further information: Investor Relations Contact, Daniel Southern-Dwyer, Corporate Development, dsd@deliccorp.com
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders.
Crop Infrastructure is engaged in the business of investing, constructing, owning and leasing mega-greenhouse projects as part of the provision of turnkey real estate solutions for lease-to-licensed cannabis producers and processors offering best-in-class operations.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
